This clinical trial is focused on studying the effects of a treatment for Parkinson’s disease, specifically in its early stages. Parkinson’s disease is a condition that affects movement, causing symptoms like tremors, stiffness, and difficulty with balance and coordination. The treatment being tested is called prasinezumab, which is given as a solution through an intravenous (IV) infusion. This means the medication is delivered directly into the bloodstream through a vein. Prasinezumab is also known by other names, such as RO7046015 and RG7935.

The purpose of this study is to evaluate how effective prasinezumab is compared to a placebo in delaying the progression of motor symptoms in people with early Parkinson’s disease. Participants in the study will receive either prasinezumab or a placebo through IV infusions. The study will monitor the time it takes for participants to experience a confirmed worsening of their motor symptoms. This will help researchers understand if prasinezumab can slow down the progression of the disease.

Throughout the study, participants will be regularly assessed to track any changes in their motor function and overall health. This includes monitoring for any side effects or adverse reactions to the treatment. The study aims to provide valuable information on the safety and effectiveness of prasinezumab for individuals with early Parkinson’s disease, potentially leading to better treatment options in the future.